FreeStyle Libre has been proven to increase Time in Range by 43%3

More frequent scanning of the FreeStyle Libre sensor has been proven to increase Time in Range
Non-insulin therapy
After 22 weeks
In people with T2D who were using non-insulin therapy and FreeStyle Libre (p<0.001 vs. baseline A1c)21
Baseline A1c:
10.1%
Follow-up A1c:
8.5%
More frequent scanning of the FreeStyle Libre sensor has been proven to increase Time in Range
Reduction in hospital admissions
Use of FreeStyle Libre reduced diabetes related hospital admissions11
Reduction in work absenteeism
Use of FreeStyle Libre led to reduction in work absenteeism over 1 year11
Disclaimer - Images are for illustration purpose only. No actual patient data. Any person depicted in the photos is a model
¶ Hospital admission decreased from 13.7% to 4.7% at 12 months (p=0.005). This study was done with the FreeStyle Libre system on 1365 people with type 1 and type 2 diabetes on insulin. The duration of the study was 1 year and the findings were measured A1c levels, hypoglycaemic and patient-reported outcomes.13
Abbreviations: HbA1c: glycated haemoglobin; MDI: multiple daily injections; SMBG: self-monitoring of blood glucose; T2D: type 2 diabetes.
References: 8. Charleer S, et al. Quality of Life and Glucose Control After 1 Year of Nationwide Reimbursement of Intermittently Scanned Continuous Glucose Monitoring in Adults Living With Type 1 Diabetes (FUTURE): A Prospective Observational Real-World Cohort Study. Diabetes Care 2020;43(2):389-397. https://doi.org/10.2337/dc19-1610. 11. Fokkert M, et al. Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4). BMJ Open Diabetes Research and Care 2019;7:e000809. doi: 10.1136/bmjdrc-2019-000809. 15. Hirst JA, et al. Quantifying the effect of metformin treatment and dose on glycemic control. Diabetes Care. 2012 Feb;35(2):446-54. doi: 10.2337/dc11-1465. 17. Miller E, Brandner L, Wright E. HbA1c reduction after initiation of the FreeStyle Libre system in type 2 diabetes patients on long-acting insulin or non-insulin therapy [84-LB]. Poster presented at: American Diabetes (ADA) 80th Scientific Sessions. 21. Wright E, et al. Diabetes Spectrum. Use of Flash Continuous Glucose Monitoring Is Associated With A1C Reduction in People With Type 2 Diabetes Treated With Basal Insulin or Noninsulin Therapy. 2021;34(2):184–189. https://doi.org/10.2337/ds20-0069.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.
The website that you have requested also may not be optimized for your screen size.
Do you wish to continue and exit this website?